Chromatine/Épigénétique
Les inhibiteurs de la chromatine/épigénétique sont des composés qui modulent la structure et la fonction de la chromatine ou interfèrent avec les modifications épigénétiques, telles que la méthylation de l'ADN et la modification des histones. Ces inhibiteurs sont des outils essentiels pour étudier la régulation de l'expression génique et le rôle de l'épigénétique dans des maladies telles que le cancer, les troubles neurologiques et les anomalies du développement. En ciblant les processus épigénétiques, ces inhibiteurs peuvent modifier les schémas d'expression génique et offrir de nouvelles perspectives thérapeutiques. Chez CymitQuimica, nous offrons une large sélection d'inhibiteurs de la chromatine/épigénétique de haute qualité pour soutenir vos recherches en biologie moléculaire, génétique et épigénétique.
Sous-catégories appartenant à la catégorie "Chromatine/Épigénétique"
2242 produits trouvés pour "Chromatine/Épigénétique"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
LSD1-IN-22
<p>LSD1-IN-22: potent LSD1 inhibitor, K_i 98 nM, curbs cancer cell growth.</p>Formule :C9H8BrF2NCouleur et forme :SolidMasse moléculaire :248.07PARP-1/HDAC-IN-1
CAS :<p>PARP-1/HDAC-IN-1 is a PARP-1 and HDAC6 inhibitor with anticancer, antimigratory, and antiangiogenic activities and is used in tumor research.</p>Formule :C22H18N4O4Degré de pureté :95.94%Couleur et forme :SolidMasse moléculaire :402.4Pociredir
CAS :<p>Pociredir (FTX-6058), a potent EED inhibitor (KD=0.163 nM), may help in SCD research.</p>Formule :C22H18FN5O2Couleur et forme :SolidMasse moléculaire :403.41PRMT5-MTA-IN-3
CAS :<p>PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It inhibits the proliferation of MTAP-deficient colorectal cancer HCT-116 cell line with an IC50 value of 5 nM. PRMT5-MTA-IN-3 holds potential for research in cancers, particularly in MTAP-deficient tumors such as colorectal cancer, non-small cell lung cancer, and pancreatic cancer.</p>Formule :C19H17F3N6O3Couleur et forme :SolidMasse moléculaire :434.372GDC-0339
CAS :GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.Formule :C20H22F3N7OSCouleur et forme :SolidMasse moléculaire :465.5LSD1-IN-15
<p>LSD1-IN-15 inhibits LSD1, MAO-A/B with IC50s: 0.149, 0.028, 0.327 μM; arrests LNCaP cancer cell growth, IC50 9.9 μM.</p>Formule :C22H20N2OCouleur et forme :SolidMasse moléculaire :328.41Purinostat
CAS :<p>Purinostat is a selective inhibitor of HDACI/IIb with potential anti-leukemic properties. Its mesylate form, Purinostat mesylate, is effective at inhibiting the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDACI/IIb, impacting several crucial factors for leukemia stem cell (LSC) survival, such as c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Additionally, Purinostat mesylate enhances glutamate metabolism in LSCs by increasing GLS1.</p>Formule :C23H26N10O3Couleur et forme :SolidMasse moléculaire :490.518CREB-IN-1 TFA
<p>CREB-IN-1 TFA: Potent oral CREB inhibitor, IC50 of 0.18 μM, suppresses breast cancer cell growth.</p>Couleur et forme :SolidJTZ-951 HCl
CAS :<p>JTZ-951 is a potent and orally active inhibitor of hypoxia inducible factor prolyl hydroxylase (PHD).</p>Formule :C17H17ClN4O4Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :376.79AMPK activator 16
CAS :<p>AMPK activator16 (compound 6) functions as an AMP-activated protein kinase (AMPK) inhibitor. It interacts effectively with crucial AMPK residues, significantly activating the enzyme. In N2a cells, AMPK activator16 enhances the expression of phosphorylated AMPK (p-AMPK) and its downstream signaling proteins, such as phosphorylated ACC (Acetyl-CoA Carboxylase) and phosphorylated raptor (p-raptor).</p>Formule :C23H20ClNO5SCouleur et forme :SolidMasse moléculaire :457.927LSD1-IN-39
CAS :<p>LSD1-IN-39 (Compound 14) is a reversible inhibitor of LSD1 with an IC50 of 0.18 μM, showing broad-spectrum antiproliferative activity against cancer cells, inhibiting HepG2 cell migration, and suppressing epithelial-mesenchymal transition. Additionally, LSD1-IN-39 exhibits antitumor activity in mouse models.</p>Formule :C25H30N2O7Couleur et forme :SolidMasse moléculaire :470.515DDO-3055
CAS :<p>DDO-3055 is an orally active PHD2 inhibitor utilized in studies related to anemia associated with chronic kidney disease.</p>Formule :C17H13ClN2O5Couleur et forme :SolidMasse moléculaire :360.749lirucitinib
CAS :<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formule :C16H25N5OSCouleur et forme :SolidMasse moléculaire :335.468LNK01004
CAS :<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formule :C26H31N7O2Couleur et forme :SolidMasse moléculaire :473.57HIF-2α-IN-5
CAS :<p>HIF-2α-IN-5 is a potent HIF-2α inhibitor with an IC 50 of < 50 nM [1].</p>Formule :C15H12F4O3S2Couleur et forme :SolidMasse moléculaire :380.38DS79932728
CAS :<p>DS79932728 is an orally active inhibitor of G9a and GLP, with IC50 values of 12.6 nM and 75.7 nM, respectively. It induces the production of γ-globin, thereby increasing fetal hemoglobin (HbF) levels. In cynomolgus monkey models, DS79932728 enhances the proportion of F-reticulocytes (F-rets) and shows good oral absorption characteristics.</p>Formule :C19H25N3OCouleur et forme :SolidMasse moléculaire :311.421PRMT5-IN-48
CAS :<p>PRMT5-IN-48 (compound D3) is an orally active PRMT5 inhibitor with an IC50 of 20.7 nM, displaying antitumor activity. It effectively suppresses the growth of various cancer cells, induces apoptosis, and causes cell cycle arrest at the G0/G1 phase. PRMT5-IN-48 is applicable for research in non-Hodgkin's lymphoma (NHL).</p>Formule :C30H37N5O3Couleur et forme :SolidMasse moléculaire :515.646HDAC11-IN-2
CAS :<p>HDAC11-IN-2 (compound B6) is a highly selective inhibitor of Histone Deacetylase 11 (HDAC11). It demonstrates IC50 values of 51.1 ×10^-3 μM for HDAC11 and 5 μM for HDAC8. HDAC11-IN-2 reduces de novo lipogenesis (DNL) and enhances fatty acid oxidation, which alleviates hepatic lipid accumulation and pathological symptoms in MASLD mice. By inhibiting HDAC11, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at the Thr172 site, thereby modulating de novo lipogenesis and fatty acid oxidation in the liver.</p>Formule :C25H35N3O3Couleur et forme :SolidMasse moléculaire :425.564Milpecitinib
CAS :<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formule :C20H20N4O2SCouleur et forme :SolidMasse moléculaire :380.463SIRT-IN-6
CAS :<p>SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with an IC50 value of >50 μM. It shows potential as a research agent for studies involving metabolic disorders, inflammation, cancer, and neurodegenerative diseases.</p>Formule :C7H4ClN3OSCouleur et forme :SolidMasse moléculaire :213.644
